Circulating Biomarkers for Immunotherapy Resistance in Liver Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to track changes in the make-up of your tumor that occur during your treatment.

What is the Condition Being Studied?

Hepatocellular Carcinoma (Liver Cancer)

Who Can Participate in the Study?

Adults with hepatocellular carcinoma (liver cancer) who will begin treatment with an immune checkpoint inhibitor.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Provide samples of blood, stool, and tumor tissue
- Have your progress tracked by the study team.

You may also be asked to undergo a tumor biopsy.

Study Details

Full Title
Identification of Circulating Biomarker Candidates for Immunotherapy Resistance in hepatocellular Carcinoma (Biobank HCC)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00108320
NCT: NA
Phase
Phase N/A
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698